CRVS Corvus Pharmaceuticals Inc
Price (delayed)
$3.21
Market cap
$218.72M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.02
Enterprise value
$211.1M
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus' lead product candidate is CPI-006, a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells
Highlights
The debt has contracted by 18% YoY
Corvus Pharmaceuticals's equity has surged by 162% QoQ but it has decreased by 16% YoY
The quick ratio has soared by 63% from the previous quarter but it has plunged by 63% YoY
Corvus Pharmaceuticals's net income has shrunk by 130% YoY and by 10% QoQ
The EPS has shrunk by 82% YoY and by 11% QoQ
Key stats
What are the main financial stats of CRVS
Market
Valuations
Earnings
Shares outstanding
68.14M
Market cap
$218.72M
Enterprise value
$211.1M
Price to earnings (P/E)
N/A
Price to book (P/B)
6.33
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$27.54M
Net income
-$62.29M
EBIT
-$62.29M
EBITDA
-$62.21M
Free cash flow
-$25.42M
Per share
Balance sheet
Liquidity
EPS
-$1.02
EPS diluted
-$1.02
Free cash flow per share
-$0.42
Book value per share
$0.51
Revenue per share
$0
TBVPS
$1.13
Total assets
$68.91M
Total liabilities
$36.34M
Debt
$1.12M
Equity
$32.57M
Working capital
$19.01M
Debt to equity
0.03
Current ratio
1.54
Quick ratio
1.47
Net debt/EBITDA
0.12
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-107.2%
Return on equity
-192.3%
Return on invested capital
-254.2%
Return on capital employed
-185.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRVS stock price
How has the Corvus Pharmaceuticals stock price performed over time
Intraday
1.26%
1 week
-4.18%
1 month
-20.54%
1 year
72.58%
YTD
-40%
QTD
0.94%
Financial performance
How have Corvus Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$27.54M
Net income
-$62.29M
Gross margin
N/A
Net margin
N/A
Corvus Pharmaceuticals's net income has shrunk by 130% YoY and by 10% QoQ
The operating income has declined by 18% year-on-year and by 10% since the previous quarter
Growth
What is Corvus Pharmaceuticals's growth rate over time
Valuation
What is Corvus Pharmaceuticals stock price valuation
P/E
N/A
P/B
6.33
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has shrunk by 82% YoY and by 11% QoQ
Corvus Pharmaceuticals's equity has surged by 162% QoQ but it has decreased by 16% YoY
The price to book (P/B) is 89% higher than the 5-year quarterly average of 3.3 but 40% lower than the last 4 quarters average of 10.5
Efficiency
How efficient is Corvus Pharmaceuticals business performance
The company's return on assets has shrunk by 112% YoY
The ROE is down by 15% since the previous quarter
Corvus Pharmaceuticals's return on invested capital has decreased by 11% QoQ
Dividends
What is CRVS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRVS.
Financial health
How did Corvus Pharmaceuticals financials performed over time
The total assets is 90% more than the total liabilities
CRVS's current ratio has soared by 67% from the previous quarter but it has plunged by 62% YoY
The quick ratio has soared by 63% from the previous quarter but it has plunged by 63% YoY
The debt is 97% less than the equity
Corvus Pharmaceuticals's equity has surged by 162% QoQ but it has decreased by 16% YoY
The debt to equity has declined by 25% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.